Form 4: MindMed CLO Sells Shares for Tax Obligations

Mind Medicine (MindMed) Inc.'s Chief Legal Officer, Mark Sullivan, sold 11,278 common shares at $9.77 each to cover tax obligations related to vested restricted stock units.

Summary

• Mark Sullivan, Chief Legal Officer of Mind Medicine (MindMed) Inc., reported a sale of 11,278 common shares.
• The transaction occurred on September 25, 2025, at a price of $9.77 per share.
• The sale was executed to satisfy withholding tax obligations arising from the settlement of vested restricted stock units.
• This transaction was conducted under a pre-arranged Rule 10b5-1 plan adopted on March 14, 2024.
• Following the sale, Mark Sullivan directly beneficially owns 293,852 common shares.
• A Power of Attorney was executed on September 24, 2025, by Mark Sullivan, appointing Brandi Roberts, Mark Sullivan, Anjeanette Bowman, and John Sharrar as attorneys-in-fact for SEC filings.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell-to-cover' for tax obligations under a pre-arranged plan, which is a neutral event. It does not indicate positive or negative sentiment towards the company's prospects.

Positives

• The transaction was pre-planned under a Rule 10b5-1 plan, indicating a structured approach to equity management rather than an opportunistic sale.

Negatives

• The sale reduces the direct equity holdings of a key executive, though it is for a routine tax obligation.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This routine insider transaction, a 'sell-to-cover' for tax purposes under a pre-arranged 10b5-1 plan, is a common occurrence for executives receiving equity compensation. It does not reflect any specific industry trends or competitive positioning for Mind Medicine (MindMed) Inc. within the biotechnology or pharmaceutical sector.

Comparison to Industry Standards

• This is a standard insider transaction for tax purposes, common across all industries for executives with equity compensation.
• The transaction volume and value are typical for an executive's tax-related sale and do not indicate any unusual activity compared to peers in the biotech industry.

Related Party Transactions

• Mark Sullivan, Chief Legal Officer, is a related party to Mind Medicine (MindMed) Inc. The reported sale of shares is a transaction between a related party and the company's equity, albeit for tax purposes related to compensation.

Stakeholder Impact

• Shareholders: Minimal impact as it's a routine tax-related sale by an executive, not indicative of a change in confidence or significant divestment.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Next Steps

• The filing does not explicitly mention any future actions, events, or milestones for the company or the reporting person beyond the ongoing compliance with SEC filing requirements.

Key Dates

Recommendation

The filing reports a routine insider transaction where the Chief Legal Officer sold shares to cover tax obligations from vested restricted stock units, executed under a pre-arranged 10b5-1 plan. This type of transaction is generally considered neutral and does not provide new information that would warrant a change in investment recommendation. It reflects standard executive compensation practices rather than a change in the company's fundamentals or outlook. Therefore, a 'hold' recommendation is appropriate as the filing does not present a compelling reason to buy or sell.

Keywords

Mind Medicine, MindMed, MNMD, SEC Form 4, Insider Trading, Stock Sale, Chief Legal Officer, Mark Sullivan, Restricted Stock Units, Rule 10b5-1, Tax Obligations